This webinar focuses on the intriguing interplay between inflammatory bowel diseases (IBD) and neutrophil activity, with a special emphasis on the insights provided by the unique CPa9-HNE serum calprotectin.
Our experts will unravel the biological processes of mucosal damage and healing in inflammatory bowel disease (IBD), and how it relates to neutrophil activity and the extracellular matrix (ECM). Specifically, we will delve into the role of mucosal damage, intestinal fibrosis, and fibro-inflammation, and how they impact ECM remodeling and integrity.
Agenda
- The role of neutrophil activity in tissue destruction – Dr. Morten A. Karsdal
- Mucosal damage and intestinal fibrosis in IBD – Dr. Florian Rieder
- Fibro-inflammation in IBD a new frontier and how to quantify it – Dr. Joachim Høg Mortensen
- Questions from the chat
Scientific topics and speakers
In this edition of the ECM Pharmacology Symposium Series, we will address the mechanisms of neutrophil activity in chronic diseases, in particular on fibro-inflammation in inflammatory bowel diseases, focusing in particular on fibro-inflammation and mucosal damage.
We will also present the latest methods for quantifying fibro-inflammation in IBD, such as the novel serum calprotectin biomarker CPa9-HNE, and discuss the implications of these findings for patients. In addition, we will look at current and future treatment options for IBD and the potential impact of these advances on patient outcomes.
This webinar is an excellent opportunity for researchers, clinicians, and healthcare professionals to gain valuable insight into the latest developments in IBD research and treatment, and to gain a deeper understanding of the intricate interplay of neutrophil activity, mucosal damage and fibro-inflammation in IBD.
Florian Rieder, MD
- Dr. Rieder’s clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction, and therapy of intestinal fibrosis.
- Dr. Rieder has published over 150 articles (h-index 52) and book chapters and he has been awarded the Sherman Emerging Leaders award.
- He is the lead author of the ECCO guidelines on Ulcerative colitis and the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He is a past associate editor of Clinical and Translational Gastroenterology.
- Dr. Rieder serves as an abstract reviewer for all major GI conferences and on several editorial boards of medical journals.
- Dr. Rieder has significant ties to the ECCO, having served as the chair of Y-ECCO, a member of the ECCO operational board, a prior Y-ECCO committee member, and a member of the scientific committee.
- He was the past chair of REACH-IBD and is currently the Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation.
- Dr. Rieder is the leading Principal Investigator (PI) of the international Stenosis Therapy and Research (STAR) Consortium, which aims to test anti-fibrotic medications in stricturing Crohn’s disease.
Dr. Joachim Høg Mortensen
- Dr. Mortensen joined Nordic Bioscience in 2013 and currently serves as Head of Department of Gastrointestinal Diseases.
- The group’s research activities span from biomarker discovery to preclinical and clinical trial exploration focusing on the development and validation of blood-based biomarkers to quantify fibro-inflammation which covers neutrophil activity, mucosal damage and intestinal fibrosis in serum of patients with gastrointestinal diseases e.g. inflammatory bowel disease.
- The group’s primary focus is to evaluate pharmacodynamics changes, efficacy and monitoring of response to various treatments using biomarkers reflecting fibro-inflammation.
- Biomarkers are developed to support and understand fibro-inflammation-associated IBD disease progression and response to treatment, where the biomarkers are applied from target selection to clinical trial monitoring.
Dr. Morten A. Karsdal
- Dr. Karsdal chairs the Extracellular Matrix Pharmacology Congress, an influential forum dedicated to advancing drug development by identifying changes in the ECM as common denominators in chronic diseases.
- Dr. Morten Karsdal joined Nordic Bioscience in 2001 and has been serving as CEO since June 2010.
- He is a prolific author, with more than 650 peer-reviewed articles to his name, accumulating over 34,000 citations and an h-index of 95.
- He is renowned for his expertise and commitment to biomarker development, extracellular matrix biology, and disease research, particularly in fibrosis, rheumatology, and diabetes. He possesses extensive experience in clinical trial design and the clinical application of biochemical markers, consulting for major pharmaceutical companies.
- As an honorary professor of inflammation research at the University of Southern Denmark, Dr. Karsdal supervises PhD students and contributes to advancing scientific knowledge in the field.
- In 2016, he authored the first edition of “Biochemistry of Collagens, Laminins and Elastin,” published by Elsevier Science, which is now in its 3rd edition, providing a comprehensive overview of structural proteins and their relevance in chronic diseases.
- Dr. Karsdal’s leadership and contributions to the Nordic Life Science community were recognized with the Arthur D. Little Nordic Life Science Award in 2023, highlighting his outstanding management and leadership achievements.
